Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’ (pharmavoice.com)
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
Formation Bio taps Biogen, Pfizer asylum to ramble R&Ds 'boring middle' |
